Reflecting on a Decade of Sofosbuvir Use for Hepatitis C Virus Treatment – Gastroenterology & Hepatology
Ira M. Jacobson, MD Professor of Medicine Director of Hepatology Research NYU Langone Health New York, New York G & H Sofosbuvir was approved with ribavirin or pegylated interferon plus ribavirin just over 10 years ago for the treatment of hepatitis C virus infection. Thinking back over the past decade of its use, why was sofosbuvir studied in this area in the first place? IJ Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus (HCV) NS5B polymerase. The drug mimics one of the normal building